ABSTRACT In patients with acute severe asthma, 5 mg of terbutaline by inhalation and 500 ,Lg intravenously in divided doses both produced equally effective but not maximal bronchodilatation. There was no difference in the production of side-effects. These results support the view that inhaled therapy can be as effective in patients with acute severe asthma as injected treatment. In view of the risks of intravenous treatment, especially using high doses, inhaled bronchodilator therapy would seem advisable as initial treatment.
In severe asthma, bronchodilators are usually given intravenously or by inhalation. We report a doubleblind crossover study which compared the bronchodilation produced by a /2 agonist (terbutaline)
given intravenously and by inhalation to determine effectiveness and the optimal dose of terbutaline by each route.
Methods
Fifteen patients admitted to hospital with severe acute asthma (Po2 < 70 mmHg, pulse > 100/min, FEV1 < 250 predicted) were studied. Patients who had been given inhaled or intravenous bronchodilators within the previous two hours were excluded. All gave their formal consent. Their FEV1 and FVC (best of three attempts) and pulse rate, were recorded on admission and again 10 minutes later.
If the recordings were stable (within ± 10%) the study was continued. The patients were then given either terbutaline 250 Hrg intravenously and 5 ml of saline by nebuliser simultaneously over 10 minutes, or saline by intravenous injection and 2 5 mg of terbutaline by nebuliser simultaneously over 10 minutes.
Spirometry (best of three recordings) and pulse rate were recorded immediately after completion of each treatment and at five-minute intervals until there was no further itnprovement in FEV1. The treatment was then repeated using the same route for the active drug and further measurements re-corded. When a new FEV1 plateau had been reached, terbutaline was given in the same two doses using the other route and the same measurements recorded.
Patients therefore received 2-5 mg of terbutaline by inhalation x 2 followed by 250 pLg of terbutaline intravenously x 2 or 250 ,tg of terbutaline intravenously x 2 followed by 2-5 mg of terbutaline by inhalation x 2. Each injection and inhalation was given over 10 minutes. The drugs were identified by code number only and the order of treatment was allocated randomly. Other treatment for severe asthma-for example, hydrocortisone 200 mg six-hourly and oxygen-was given concurrently in all cases but intravenous aminophylline was not used.
Results
In eight patients terbutaline was first given intravenously and then by inhalation. In seven patients the active drug was initially given by inhalation and then intravenously. The results are shown in the figure.
Both routes produced significant improvement in FEV1 and FVC and fall in pulse rate and there was no significant difference between them. Neither 5 mg inhaled terbutaline nor 500 ,ug of intravenous terbutaline produced maximal bronchodilation, as all measurements were still improving even after both routes had been employed. No important adverse side-effects were found when the active drug was given by either route. Tremor was equally common (three cases The results showed bronchodilation to be independent of route of administration. In view of the clinical circumstances our study was kept as simple as possible and arterial oxygen tension was not followed during treatment, and we therefore cannot exclude differences in response of blood gases to the routes of administration. Although there were no differences in response between the two treatment groups the rise in the heart rate when the first intravenous dose of terbutaline was given to those who had initially been treated by inhalation is probably of clinical significance as it indicates the potential disadvantage of injected therapy. Our results do not show this as convincingly as previously reported,1 2 but lead to a similar conclusion that inhaled therapy minimises the risks of systemic sideeffects.
We carried out this study because the choice of bronchodilator, its route of administration, and optimal dose in patients with life-threatening asthma are still subjects of controversy. The /2 agonist salbutamol, given intravenously, has been shown to be as effective as aminophylline and less likely to cause nausea and vomiting.3 Lawford et a12 found that in severely ill patients intravenous salbutamol produced tremor and tachycardia whereas nebulised salbutamol did not. By contrast, in another study, intravenous salbutamol was shown to produce effective bronchodilation in patients who had failed to respond satisfactorily to inhaled salbutamol.4 However, Bloomfield et all found that both intravenous and inhaled salbutamol produced a significant improvement in peak expiratory flow but intravenous salbutamol resulted in an increase in heart rate while the inhaled drug did not and relief of pulsus paradoxus was significantly better after inhaled rather than intravenous treatment.
The most likely explanation for the different results of these and similar studies, and for differences in opinion about the best route 
